药物遗传因素对儿童吗啡及其代谢物药代动力学影响的系统综述
本系统综述检索Embase和Medline数据库,遵循PRISMA指南,最终纳入8项研究,评估遗传因素对儿童吗啡及其主要代谢物药代动力学的影响。研究提示SLC22A1和ABCC3基因变异对吗啡及其代谢物药代动力学影响的证据最多,但研究异质性和样本量小使遗传生物标志物用于个体化给药仍具挑战。
要点
- SLC22A1和ABCC3基因变异对儿童吗啡药代动力学影响的证据最多。
- 纳入研究异质性和样本量小,尚不能推荐基因检测指导儿童吗啡给药。
- 需更大规模药代动力学-药物遗传学研究验证基因检测能否优化儿童吗啡安全性和有效性。
核心结论
- 现有证据提示部分代谢酶和转运体基因变异可能参与儿童吗啡血浆浓度的个体间变异,但尚不足以推荐基因生物标志物用于个体化吗啡给药。
研究设计与样本
- 系统综述,检索Embase和Medline数据库,遵循PRISMA指南,最终纳入8项研究。
主要发现
- 纳入研究提示所选代谢酶和转运体的遗传变异可能参与观察到的吗啡血浆浓度个体间变异。
- SLC22A1和ABCC3基因变异对儿童吗啡及其代谢物药代动力学影响的证据最多。
临床怎么用
- 目前不建议常规使用基因检测指导儿童吗啡个体化给药。
局限性
- 纳入研究在实验设计方面存在异质性,部分研究样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Morphine is a potent analgesic used for treating surgical and cancer pain. Despite being the drug of choice for the management of severe pain in children, the high interindividual variability in morphine pharmacokinetics limits its clinical utility to effectively relieve pain without adverse effects. This review was conducted to identify and describe all studies that have assessed the effect of genetic factors on the pharmacokinetics of morphine and its main metabolites in children. Embase and Medline databases were used to conduct the literature search, and the systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Of the 188 articles screened and after the application of specific inclusion and exclusion criteria, the review identified 8 studies. These studies suggest that genetic variants of selected metabolic enzymes and transporters may play a role in the observed interindividual variability in morphine plasma concentrations. Variants of the genes SLC22A1 and ABCC3 had the most supporting evidence for genetic variants that influence morphine and morphine metabolites pharmacokinetics. Although the available evidence suggests a potential genetic contribution to the variability in morphine concentration, the heterogeneity of the included studies in terms of experimental design and small sample sizes in some studies makes it challenging to propose the use of genetic biomarkers to personalize morphine dosing. This underscores the need to conduct more comprehensive and large-scale pharmacokinetic-pharmacogenetic studies to determine how or if genetic testing can optimize morphine safety and effectiveness in children.
引用
- Mufti K, Juárez-Hernández JE, Gheshlaghi N, et al. The Influence of Pharmacogenetic Factors on the Pharmacokinetics of Morphine and Its Metabolites in Pediatric Patients: A Systematic Review. Anesth Analg. 2024. PMID: 39661418. doi:10.1213/ANE.0000000000007349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。